Overview
The Medical Device Coordination Group (MDCG) has published MDCG 2025-10, a new guidance document addressing post-market surveillance (PMS) requirements under both the EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR). While the guidance does not introduce new legal obligations or reinterpret the Regulations, it is nonetheless a significant publication. For the first time, it brings together in a single document a clear, practical description of what a functioning PMS system is expected to look like in practice.
The guidance shifts the focus away from PMS as a set of isolated activities and reinforces its role as a continuous, structured system embedded within the manufacturer’s quality management system. It clearly articulates how PMS should interact with risk management, clinical or performance evaluation, labelling, CAPA, and management review.
See our “How to set up a PMS System” article here.
Who is it relevant to?
MDCG 2025-10 is relevant to all manufacturers of medical devices and IVDs operating under MDR or IVDR, regardless of device class or maturity. It is particularly useful for manufacturers who are early in their MDR or IVDR transition and are still establishing or formalising PMS processes. For more established organisations, the guidance serves as an important alignment tool, helping to ensure that regulatory, quality, clinical, and post-market teams are working to the same interpretation of PMS expectations.
Notified bodies and authorised representatives are also likely to rely on this document as a common reference point when reviewing PMS systems, plans, and outputs during conformity assessments and surveillance activities.
What the guidance says
The guidance makes it clear that PMS is not limited to complaint handling or vigilance reporting. Instead, it describes PMS as a proactive, data-driven system designed to continuously monitor device performance and safety throughout the lifecycle.
Key expectations reinforced by the guidance include the systematic collection and analysis of multiple data sources, such as complaints, vigilance data, literature reviews, user feedback, trend analysis, comparisons with similar devices, and assessment against the current state of the art. The use of predefined indicators and threshold values is emphasised, with the expectation that these are used to trigger investigation, escalation, and corrective action where appropriate.
Importantly, the guidance stresses that PMS data must actively drive decisions. Outputs from PMS are expected to feed directly into risk management files, clinical or performance evaluation updates, labelling changes, CAPA, and management review. Passive reporting or retrospective compilation of PMS data is clearly not sufficient.
While these principles are already embedded within MDR and IVDR, MDCG 2025-10 articulates them in a structured and practical way that leaves little room for ambiguity.
Why this guidance matters
Although MDCG guidance is not legally binding, it is difficult to envisage notified bodies not referring to MDCG 2025-10 going forward. The document provides a shared language and framework that will inevitably influence how PMS systems and documentation are assessed.
For manufacturers, this guidance represents a natural checkpoint. It offers an opportunity to critically review whether existing PMS procedures, plans, templates, and internal understanding genuinely reflect what is now clearly described as industry best practice. In many cases, gaps are not the result of missing activities, but of weak integration, unclear responsibilities, or insufficient use of PMS outputs to drive change.
How Specculo can help
Specculo supports medical device and IVD manufacturers at all stages of PMS maturity. We help organisations design, implement, and maintain PMS systems that are compliant, proportionate, and operationally sustainable.
Our PMS support includes development and review of PMS plans and procedures, establishment of indicators and thresholds, literature and trend analysis, integration of PMS outputs into risk management and clinical or performance evaluation, and preparation for notified body review. For manufacturers with limited internal resources, we also offer tiered PMS service packages that provide predictable support aligned with regulatory expectations.
With the publication of MDCG 2025-10, now is an ideal time to assess whether your PMS system truly reflects what regulators and notified bodies expect to see in 2026 and beyond. Specculo can help you close gaps efficiently and with confidence.